Triple negative breast cancer patients presenting with low serum vitamin D levels: a case series by Rainville, Christa et al.
Case report
Open Access
Triple negative breast cancer patients presenting with low serum
vitamin D levels: a case series
Christa Rainville*, Yasir Khan and Glenn Tisman
Address: A Medical Corporation, 13025 Bailey Street, Suite A, Whittier, CA 90601, USA
Email: CR* - christa324@gmail.com; YK - portal002@gmail.com; GT - glennmd@gmail.com
*Corresponding author
Received: 22 June 2009 Accepted: 1 July 2009 Published: 21 July 2009
Cases Journal 2009, 2:8390 doi: 10.4076/1757-1626-2-8390
This article is available from: http://casesjournal.com/casesjournal/article/view/8390
© 2009 Rainville et al; licensee Cases Network Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0),
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Introduction: Serum vitamin D levels measured as 25-hydroxyvitamin D have been shown to be
low in cancer patients, including breast cancer patients. However, the vitamin D status has yet to be
studied in different breast cancer phenotypes: luminal A, luminal B, HER2+/ER-, and triple negative
comprising the majority of basal-like.
Case presentation: Fifteen triple-negative breast cancer patients have presented to our medical
oncology office in the last five years. Thirteen of these fifteen patients (87%) were found to be vitamin
D deficient, defined as serum 25(OH)D less than 80 nmol/L, prior to initiation of adjuvant therapy.
Ninety-one breast cancer patients from our office were classified as: luminal A (ER+ &/or PR+ and
HER2-), luminal B (ER+ &/or PR+ and HER2+), HER2+/ER- (ER-, PR-, and HER2+), and triple-
negative or basal-like (ER-, PR-, and HER2-). A normal mean was found from 78 volunteers. The
breast cancer patients were found to be statistically different than the normal population. The triple-
negative phenotype was found to be the most statistically different than the normal population.
Conclusion: The triple-negative breast cancer phenotype has the lowest average vitamin D level and
the highest percentage of patients that are vitamin D deficient. These data suggests that low vitamin D
levels are characteristic of the triple-negative phenotype.
Introduction
Studies have shown that breast cancer incidence, mortality
and survival rates are inversely correlated with solar UVB
irradiance and/or serum vitamin D levels. In North
America, breast cancer mortality rates are highest in the
northeast where ultraviolet B radiation levels allow
decreased synthesis of vitamin D during a large part of
the year. This area tends to have age-adjusted mortality
rates that are about 40% higher than in Hawaii and
considerably higher than in high sun-exposure regions of
the southwest [1].
There are two major forms of vitamin D in the body; 25-
hydroxyvitamin D (25(OH)D) and 1,25-dihydroxyvitamin
D (1,25(OH)2D). 25(OH)D is the storage form of vitamin
D. It circulates in the blood and is the best indicator for
vitamin D status in the body. 25(OH)D is hydroxylated in
the kidney to become 1,25-dihydroxyvitamin D, which is
the biologically active form of vitamin D [2].
It was found in 2001 that many tissues are able to directly
convert circulating 25(OH)D to 1,25(OH)2D, including
mammary tissue [3]. This focuses more attention on the
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precursor 25(OH)D. It has been shown that 1,25(OH)
2D, inhibits cell proliferation and induces apoptosis in
breast cancer cells in vitro. In animal models, vitamin D
analogues slowed down tumor development and pro-
moted regression of established mammary tumors [4].
One group found that mean serum levels of 25(OH)D
were significantly lower in breast cancer patients with
locally advanced or metastatic disease. They showed that
the mean 25(OH)D was statistically lower in advanced-
stage breast cancer patients compared to early-stage breast
cancer. The authors suggested that the lower serum
vitamin D levels might have some causative role in the
progression from early-stage to advanced disease as a
result of altered gene transcription. They concluded that
their findings lend support to the hypothesis that vitamin
D has a role in the pathogenesis and progression of breast
cancer [5].
Goodwin et al, who were measuring all-cause mortality
rates in breast cancer patients, found that women who
had vitamin D deficiency (<50 nmol/L) when they were
diagnosed with breast cancer were 94% more likely to
have their cancer metastasize and 73% more likely to die
within 10 years. The team also found that only 24% of the
women in the study had adequate levels of vitamin D
(>72 nmol/L) at the time of the diagnosis [6].
One of the newer phenotypic classifications for breast
cancer is based on immunohistochemical and FISH
analysis of tumor cell estrogen receptor (ER), progesterone
receptor (PR) and HER2 neu (HER2) expression. Luminal
A tumors are those that are ER + and/ or PR + and HER2 -.
Luminal B tumors are ER + and/or PR + and HER2 +. This
definition of luminal B tumors only identifies 30% to
50% that are HER 2 +. The other luminal B tumors with
HER2 negativity would be classified under the luminal A
subtype. HER2 +/ER- phenotype is HER2+, ER -, and PR -.
Approximately 80% of triple negative tumors are basal-
like tumors that are ER -, PR -, and HER2 -, a portion of this
group is represented by BRCA 1 tumors. We are aware that
various investigators have defined similar but not neces-
sarily identical subgroups by including other markers such
as tumor grade, cytokeratins and HER1 expression.
However, most agree that tumors negative for the three
markers HER2, ER and PR (triple negative) belong in the
basal-like subgroup [7].
Though low vitamin D levels are associated with advanced
stage disease and patients who develop metastases,
vitamin D status has yet to be studied within the newly
established breast cancer phenotypes. This case series
observed low vitamin D levels in thirteen of fifteen
patients with the triple negative phenotype.
Case presentation
Ninety-one newly diagnosed breast cancer patients’ base-
line vitamin D levels were obtained from our medical
oncology office population in sunny Whittier, California
in the last five years. Sixty-five were classified as Luminal A,
six were classified as Luminal B, five were classified as
HER2+/ER-, and fifteen were classified as triple-negative or
basal-like. Baseline vitamin D levels were measured as
25(OH)D prior to any adjuvant therapy. Table 1 shows
each patients’ age, ethnicity and baseline vitamin D level
as 25(OH)D.
Table 1. Triple Negative Patients’ Baseline Vitamin D Level, Age and
Ethnicity
Classification Baseline Serum
25(OH)D (nmol/L)
Age Ethnicity
Luminal A 125.0 51 WNH
Luminal A 49.0 81 WNH
Luminal A 107.0 67 WNH
Luminal A 63.0 83 WNH
Luminal A 33.7 75 WNH
Luminal A 102.0 83 WH
Luminal A 98.0 65 WNH
Luminal A 59.3 53 WNH
Luminal A 28.0 61 WNH
Luminal A 123.9 76 WNH
Luminal A 64.0 63 WNH
Luminal A 54.0 66 WNH
Luminal A 112.2 85 WNH
Luminal A 92.0 62 WNH
Luminal A 60.0 69 WNH
Luminal A 31.2 90 WNH
Luminal A 96.0 74 A
Luminal A 95.4 72 WHN
Luminal A 300.0 75 WHN
Luminal A 74.7 50 WHN
Luminal A 50.0 69 WHN
Luminal A 53.0 65 WHN
Luminal A 11.7 80 WHN
Luminal A 101.0 64 WHN
Luminal A 84.0 80 WHN
Luminal A 66.6 74 WHN
Luminal A 86.0 62 WHN
Luminal A 125.0 39 WH
Luminal A 117.0 69 WNH
Luminal A 61.0 80 B
Luminal A 36.0 74 WNH
Luminal A 16.0 84 WNH
Luminal A 61.0 59 WNH
Luminal A 82.0 68 WNH
Luminal A 9.0 107 WNH
Luminal A 57.6 87 WNH
Luminal A 72.0 79 WNH
Luminal A 213.6 77 WNH
Luminal A 35.0 78 WNH
Luminal A 68.0 49 B
Luminal A 50.0 63 WNH
Luminal A 67.0 84 WNH
Luminal A 44.0 83 WNH
Luminal A 208.8 79 WNH
Luminal A 81.0 90 WNH
Luminal A 105.0 67 WNH
Luminal A 23.5 72 WNH
Luminal A 56.4 70 WNH
(Continued)
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patients in standard serum separator vacutainer tubes with
gel and clot activator and allowed to clot at room
temperature (Franklin Lakes, NJ) [8]. After 15-30 minutes
the tubes were centrifuged and serum was separated and
stored frozen at -40 degrees centigrade for less than
2 weeks.
An Immunodiagnostic System (IDS) 25-hydroxyvitamin
D kit by EIA method was used on a DSX system analyzer
by DYNEX. We are currently involved in a program by
Vitamin D External Quality Assessment Scheme (DEQAS)
based in London that assesses the accuracy of our
25(OH)D levels compared to laboratories across the
world. Our laboratory reached to performance target set
by the DEQAS Advisory Panel for the 2007-2008 year.
Thirteen out of fifteen (87%) of the triple negative patients
were vitamin D deficient as defined as less than 80 nmol/L
[9]. The other two patients were very close to being
deficient, having vitamin D levels of 80.0 nmol/L and
82.4 nmol/L. When looking at all of our breast cancer
patients (91 total), we found that 54 patients (62%) had
baseline vitamin D levels in the deficiency range
<80 nmol/L. Of our 91 breast cancer patients, 65 were
found to belong to the Luminal A subtype (ER + and/ or
PR + and HER2 -), six were Luminal B subtype (ER + and/
or PR + and HER2 +), five were the HER2+/ER- subtype
(HER2+, ER -, and PR -), and 15 were classified as the
triple-negative subtype (ER-, PR-, HER2-). A normal
control population was established from a community
outreach program to Whittier, CA non-hospitalized
residents, which included 78 volunteers that did not have
cancer. Table 2 shows the mean, median, standard
deviation and percent deficient for each group. The mean
± standard deviation for serum vitamin D levels were as
follows:normalvolunteers(90±40nmol/L),breastcancer
patients (76 ±50), luminal A (79 ± 50 nmol/L), luminal B
(75 ± nmol/L 30), HER2+/ER- (93 ± 30 nmol/L), and
triple-negative or basal-like (50 ± 20 nmol/L). The triple
negative phenotype had the lowest average and median
baseline vitamin D level and had the highest percentage
with vitamin D deficiency.
To assess whether vitamin D levels were statistically lower
in cancer patients than normal and whether vitamin D
differed by tumor stage we used the unpaired t-test with
significance level, a, of 0.05 (Table 3). The unpaired t-test
showed that breast cancer patients have significantly lower
vitamin-D levels than normal, p < 0.015 and we could not
find statistical difference by tumor stage. Further analysis
Luminal A 23.0 61 WNH
Luminal A 34.3 55 WH
Luminal A 65.0 80 WNH
Luminal A 88.0 81 WNH
Luminal A 14.0 73 WNH
Luminal A 91.0 52 WH
Luminal A 68.0 55 WNH
Luminal A 99.0 68 WNH
Luminal A 61.0 77 WNH
Luminal A 185.1 62 WH
Luminal A 18.4 63 WNH
Luminal A 65.5 48 WNH
Luminal A 75.1 83 WNH
Luminal A 89.0 WNH
Luminal A 238.1 67 WNH
Luminal A 39.0 87 WNH
Luminal A 97.5 66 WNH
Luminal B 82.2 59 WNH
Luminal B 76.9 60 B
Luminal B 48.6 81 WHN
Luminal B 41.0 35 WHN
Luminal B 84.0 66 A
Luminal B 117.0 68 WNH
HER2/neu + 74.0 63 WNH
HER2/neu + 94.0 81 WNH
HER2/neu + 60.8 60 WNH
HER2/neu + 114.4 52 WNH
HER2/neu + 121.1 54 WNH
Triple-Negative 49.6 52 WNH
Triple-Negative 61.0 66 WH
Triple-Negative 38.0 34 WNH
Triple-Negative 22.7 89 WNH
Triple-Negative 34.7 83 WNH
Triple-Negative 45.0 79 WNH
Triple-Negative 55.0 58 WNH
Triple-Negative 77.2 76 WH
Triple-Negative 25.0 43 WNH
Triple-Negative 82.4 45 WNH
Triple-Negative 30.0 71 WNH
Triple-Negative 72.0 69 WNH
Triple-Negative 41.6 57 WNH
Triple-Negative 80.0 79 WNH
Triple-Negative 32.4 55 WNH
A, Asian; B, Black; WH, White Hispanic; WNH, White Not-Hispanic.
Table 1. Continued
Classification Baseline Serum
25(OH)D (nmol/L)
Age Ethnicity
Table 2. Sample Size, Mean 25(OH)D, Median 25(OH)D, Standard Deviation, % Vitamin D Deficient of Normal Controls and Breast Cancer Classifications
Normal Control Breast Cancer Luminal A Luminal B Her2+/ER- Triple-Negative
Sample Size 78 91 65 6 5 15
Mean Baseline Serum 25(OH)D (nmol/L) 90 76 79 75 93 50
Median Baseline Serum 25(OH)D (nmol/L) 86.0 66.6 67.0 79.5 94.0 45.0
Standard Deviation Baseline Serum 25(OH)D (nmol/L) 40 50 50 30 30 20
% Vitamin-D Deficient 43% 62% 58% 50% 40% 87%
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way ANOVA identified statistically different groups
(F = 2.56 & Significance value = 0.041). Data is shown
in Table 4. Furthermore, we used ANOVA to identify the
most statistically different breast-cancer type. Post-hoc
analysis by Tukey Honestly Statistically Different (HSD)
test, Table 5, was used to identify which type of breast
cancer was the most statistically different than normal. The
triple-negative subgroup was found to be the most
statistically different than the normal volunteers (signifi-
cance value = 0.01).
Conclusion
The finding that breast cancer patients with the lowest
serum 25(OH)D levels presented with the biologically
aggressive triple-negative tumor phenotype was not a
surprise. Others have demonstrated by in vitro studies that
breast tumor cell lines growing in the presence of limited
vitamin D frequently over-express more aggressive phe-
notypes associated with poor prognosis [10]. Compared
with luminal A, triple-negative (basal-like) tumors had
more TP53mutations (44% vs 15%),higher mitotic index,
more marked nuclear pleomorphism and higher com-
bined grade as well as poor cancer-specific survival [7].
This case series found that patients with the more
aggressive triple-negative phenotype had a mean serum
vitamin D level of 50 nmol/L compared to a mean of
90 nmol/L for normal Whittier, CA volunteers. The assay
normal cut-off was defined as >=80 nmol/L [9]. This
finding, coupled with tissue culture experiments and the
epidemiological study noted previously, suggests that the
serum vitamin D level may be important in tumor
development and phenotypic expression and the biologic
behavior of breast tumors. This hypothesis is compatible
with the fact that African American women have the
highest breast cancer specific mortality rates, the lowest
serum levels of 25(OH)D, and the highest incidence of
aggressive triple-negative or basal-like tumors (39%) [7].
This series observed that triple-negative breast cancer
patients have lower vitamin D levels than the other breast
cancer phenotypes. In addition, we found that the triple-
negative subtype is the most statistically different than
normal compared to the other subtypes. The lack of
vitamin D transport into cells may contribute to the
phenotypic expression. Further studies are warranted to
investigate possible relationships between the breast
cancer phenotypes, pathological grades, clinical stages,
and overall and cancer specific survival and vitamin D
sufficiency. We think it prudent to supplement all patients
with breast cancer and low levels of vitamin D with
adequate amounts of vitamin D3 and generally administer
2000 IU/day orally. This dose in combination with
moderate sunlight is usually enough to raise serum
25(OH)D levels to 130 nmol/L, which is associated with
a 50% reduction in incidence of breast cancer, according to
observational studies [11].
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